TARGETING ADENOSINE MEDIATED IMMUNOSUPPRESSION TO ENHANCE CAR T CELL ACTIVITY
Grant number: 1122444 | Funding period: 2017 - 2019
The use of white blood cells genetically engineered to eradicate cancer cells specifically has been a major breakthrough in cancer treatment. These cells (CAR T cells) are very effective in blood cancers, but do not currently work well in other cancers. This is due to the immune suppressing nature of the cancer environment. I propose to use strategies to overcome this by genetically reprogramming the CAR T cells to be resistant to suppression by the cancer and therefore be more effective.